COVID-19 Update: Vaccines and the Delta Variant

The delta variant of COVID-19 has put the US in the precarious position of a fourth wave of the disease -- how efficacious are our vaccines against this variant? Also, are any new treatments for early COVID-19 being studied to help continue the fight? Find out more in this episode!Redeem your CPE or CME credit here!We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964References and resources: Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30. PMID: 34192428; PMCID: PMC8262622.Rossignol J, Matthew C, Oaks J, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441Continuing Education Information:Learning Objectives: 1. Discuss the differences in effectiveness between the mRNA and adenovirus vaccines for the delta variant of COVID-192. Describe the use of nitazoxanide in mild to moderate COVID-19 and barriers to its use0.05 CEU | 0.5 HrsACPE UAN: 0107-0000-21-XXX-H01-PInitial release date: 8/31/21Expiration date: 8/24/22Complete CPE & CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram